Accuray (NASDAQ:ARAY) Shares Cross Above Two Hundred Day Moving Average - Time to Sell?

Key Points

• Accuray's share price recently crossed above its two hundred-day moving average of $1.51, reaching a high of $1.75 during trading.
• Analysts have mixed ratings for Accuray, with one upgrading the stock to a "hold" while another reaffirmed a "sell" rating, resulting in a consensus rating of "hold" and an average target price of $5.00.
• The company's latest earnings report showed a loss of $0.02 per share against expectations, despite revenue of $127.54 million exceeding forecasts.

Accuray Incorporated (NASDAQ:ARAY - Get Free Report)'s share price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.51 and traded as high as $1.75. Accuray shares last traded at $1.69, with a volume of 464,785 shares changing hands.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Wall Street Zen raised Accuray from a "sell" rating to a "hold" rating in a report on Saturday, September 13th. Weiss Ratings restated a "sell (e+)" rating on shares of Accuray in a research report on Saturday, September 27th. Finally, BTIG Research raised their price target on Accuray from $4.00 to $5.00 and gave the company a "buy" rating in a report on Thursday, August 14th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $5.00.

Accuray Stock Performance

The stock has a market cap of $190.50 million, a P/E ratio of -84.50 and a beta of 1.31. The stock has a fifty day simple moving average of $1.53 and a 200-day simple moving average of $1.51. The company has a quick ratio of 0.92, a current ratio of 1.65 and a debt-to-equity ratio of 1.53.

Accuray (NASDAQ:ARAY - Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The medical equipment provider reported $0.01 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.02). The firm had revenue of $127.54 million during the quarter, compared to analyst estimates of $123.78 million. Accuray had a negative net margin of 0.35% and a negative return on equity of 4.92%. Accuray has set its FY 2026 guidance at EPS. Equities analysts expect that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Institutional Trading of Accuray

Several hedge funds have recently added to or reduced their stakes in ARAY. Ameriprise Financial Inc. acquired a new position in Accuray in the fourth quarter valued at about $35,000. Tower Research Capital LLC TRC increased its stake in Accuray by 604.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 35,177 shares of the medical equipment provider's stock worth $48,000 after purchasing an additional 30,182 shares in the last quarter. Williams & Novak LLC raised its holdings in Accuray by 25.5% during the 2nd quarter. Williams & Novak LLC now owns 68,970 shares of the medical equipment provider's stock worth $94,000 after buying an additional 14,000 shares during the period. Deutsche Bank AG lifted its stake in Accuray by 44.0% in the first quarter. Deutsche Bank AG now owns 60,606 shares of the medical equipment provider's stock valued at $108,000 after buying an additional 18,526 shares in the last quarter. Finally, Algert Global LLC lifted its stake in Accuray by 104.7% in the first quarter. Algert Global LLC now owns 60,930 shares of the medical equipment provider's stock valued at $109,000 after buying an additional 31,170 shares in the last quarter. Institutional investors and hedge funds own 64.08% of the company's stock.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.